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Abstract With the exponential growth of cardiovascular
implantable electronic devices (CIEDs) in pediatric
patients, a new method of long-term surveillance, remote
monitoring (RM), has become the standard of care. The
purpose of this study was to determine the usefulness of
RM as a monitoring tool in the pediatric population. A
retrospective review was performed of 198 patients at the
University of Iowa Children’s Hospital who had CIEDs.
Data transmitted by RM were analyzed. The following data
were examined: patient demographics; median interval
between transmissions; detection of adverse events
requiring corrective measures, including detection of lead
failure; detection of arrhythmias and device malfunctions
independent of symptoms; time gained in the detection of
events using RM versus standard practice; the validity of
RM; and the impact of RM on data management. Of 198
patients, 162 submitted 615 RM transmissions. The median
time between remote transmissions was 91 days. Of 615
total transmissions, 16 % had true adverse events with
11 % prompting clinical intervention. Of those events
requiring clinical response, 61 % of patients reported
symptoms. The median interval between last follow-up and
occurrence of events detected by RM was 46 days,
representing a gain of 134 days for patients followed-up at
6-month intervals and 44 days for patients followed-up at
3 month-intervals. The sensitivity and specificity of RM
were found to be 99 and 72 %, respectively. The positive
and negative predictive values were found to be 41 and
99 %, respectively. RM allows for early identification of
arrhythmias and device malfunctions, thus prompting ear-
lier corrective measures and improving care and safety in
pediatric patients.
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Introduction
The use of cardiovascular implantable electronic devices
(CIEDs)—including pacemakers, cardioverter defibrillators
(ICDs), implantable loop recorders, and cardiac resyn-
chronization therapy (CRT-D and CRT-P)—in both adults
and children has grown exponentially. To ensure proper
use, these devices require regular follow-up. To address
this need, a new method of long-term surveillance, remote
monitoring (RM), has been developed. The advent of RM
systems for CIEDs offers many options and at the same
time raises many questions regarding its implementation,
organization of the obtained wealth of data, safety, legal
issues, and reimbursement [8].
Home monitoring was first introduced in 1971 with
transtelephonic monitoring of pacemakers. Within the last
decade, several device manufacturers have introduced RM
technology to enhance monitoring capabilities. RM uses
the Internet as a means to interrogate CIEDs and download
the stored information, thus allowing physicians to
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troubleshoot problems when they arise or before symp-
toms. As a result, patients may avoid extra clinic or
emergency room visits. The development and use of RM
has changed the standard for the management of patients
with implanted devices. A recent expert consensus state-
ment of the Heart Rhythm Society (HRS) and the European
Heart Rhythm Society (EHRA) affirmed the earliest pos-
sible identification of abnormal device behavior, as well as
the prevention of device malfunction underreporting, as
being the primary goal of remote CIED monitoring [9].
Recent studies have shown that RM using the Internet is
considered a milestone in the management of adult patients
with an implantable cardiac device [6, 9]. Although the
effectiveness of RM has been evaluated in adults, its use-
fulness and accuracy in the pediatric population has not
been evaluated. Children are more prone to lead malfunc-
tions; systems may be more complicated because of con-
genital heart disease; and it is challenging for young
children to describe symptoms. Accordingly, RM may
improve our ability to manage and care for these patients.
The purpose of this study was to determine the useful-
ness of RM as a monitoring tool in the pediatric population
with CIEDs by (1) evaluating the adherence of pediatric
patients with CIEDs to RM procedures; (2) evaluating
early detection of adverse events prompting corrective
measures, including detection of lead failure; (3) deter-
mining the ability of RM to detect arrhythmias and device
malfunctions independent of symptoms; and (4) evaluating
the validity of RM.
Methods
We performed a retrospective review of all patients at the
University of Iowa Children’s Hospital who had a CIED
with RM capability between March 31, 2006, and October
14, 2011. Data transmitted by an RM system [Medtronic
CareLink (Minneapolis, MN) and Boston Scientific Lati-
tude (Natick, MA)], and the patient’s medical record were
analyzed. This project was approved by the University of
Iowa Institutional Review Board.
The following were examined: Patient demographics,
median interval between remote transmissions; detection of
adverse events prompting corrective measures; time gained
in the detection of events using RM versus standard prac-
tice; sensitivity and specificity of RM; positive and nega-
tive predictive valve of RM; and the impact of RM on data
management.
The types of events detected and transmitted during the
study period were classified into groups with concerns
related to disease/rhythm (sensed arrhythmias requiring
therapy), device function (elective replacement indicator/
end of life), and lead function (fracture, impedance
changes, failure). Adverse events that prompted clinical
response as defined by Chen et al. [1] are listed in Table 1.
Clinical response was defined as an event requiring medi-
cation adjustment, pace termination, shock, cardioversion,
generator replacement, or lead replacement.
The median interval between remote transmissions was
calculated and compared with the recommended follow-up
guidelines. Only one remote transmission per day was
included in the median interval calculation. The median
time interval between first report of an event and last
device interrogation in the clinic was calculated. Assuming
the typical protocol at our institution of twice-yearly in-
person follow-up schedule for pacemaker, ICD, and CRT
system surveillance and quarterly follow-up for loop
recorders, the time gained in the detection of events using
RM versus standard practice was calculated as 180 - X
days and 90 - X days, respectively. Sensitivity was cal-
culated as follows: number of true-positive events/(number
of true-positive ? false-negative events). Specificity was
calculated as follows: number of true-negative events/
(number of true-negative ? false-positive events). Positive
predictive value was calculated as follows: number of true-
positive events/(number of true-positive ? false-positive
events). Negative predictive value was calculated as fol-
lows: number of true-negative events/(number of true-
negative ? false-negative events). True-positive events
were defined as patients with an event who were correctly
diagnosed as having an event. False-positive events were
defined as patients without an event who were incorrectly
identified as having an event. True-negative events were
defined as patients without an event who were correctly
identified as not having an event. False-negative events
were defined as patients with an event who were incor-
rectly identified as not having an event. The impact of RM
on data management was examined by evaluating the
number of remote transmissions from 2006 to 2011 and by
calculating the average number of reports received per
week and per month.
Results
Between March 31, 2006, and October 14, 2011, 198
patients had CIEDs with RM capability, including the
following: pacemakers (n = 105), cardioverter defibrilla-
tors (n = 61), implantable loop recorders (n = 27), com-
bined cardiac resynchronization therapy pacemaker
systems (n = 2), and combined cardiac resynchronization
therapy ICD systems (n = 3). Primary diagnoses included
the following: complete heart block 38 % (n = 76), sinus
node dysfunction 16 % (n = 32), ventricular arrhythmias
14 % (n = 27), syncope 8 % (n = 16), long QT syndrome
7 % (n = 13), atrial arrhythmias 6 % (n = 11), atrial and
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ventricular arrhythmias 3 % (n = 6), asystole 2 % (n = 5),
and other 6 % (n = 12). Forty-nine percent (n = 97) of
patients included in the study had congenital heart disease.
The average age of patients was 21 ± 12 years (SD), and
the median age was 18 years (range 1–63). There were 100
male and 98 female patients.
Of the 198 total patients with CIEDs during the study
period, 18 % (n = 36) did not have a remote transmission
recorded. The median time between remote transmissions
was 91 days (range 1–842). Of the 615 transmissions, 461
were remote transmissions for routine follow-up. One
hundred fifty-four transmissions were for a specific indi-
cation (patient symptoms, device alarm). Thirteen percent
(60 of 461) of remote transmissions for routine follow-up
were found to be true events, whereas 27 % (42 of 154) of
remote transmissions for a specific indication were found
to be true events. Sixteen percent of total transmissions
(n = 615) detected true adverse events (n = 101), and
11 % (n = 65) of these prompted clinical intervention. Of
the transmissions with true adverse events, 64 % (n = 65)
prompted clinical intervention. Of the patients requiring
clinical intervention, 79 % (n = 51) had disease/rhythm-
related concerns, 12 % (n = 8) had general device status
concerns, and 9 % (n = 6) had lead failure concerns
(Fig. 1). Of those with events detected by RM, 61 % of
patients had symptoms (n = 40), and 39 % (n = 25) had
no symptoms associated with the event (Fig. 2a). Of the
patients with symptoms, 95 % (n = 38) were associated
with concerns related to disease/rhythm (sensed arrhyth-
mias requiring therapy); 5 % (n = 2) were associated with
device function (elective replacement indicator/end of life);
and none were associated with lead function (fracture,
impedance changes, failure) (Fig. 2b). For patients
receiving a shock, 13 patients sent a specific transmission
for symptoms. One patient was noted to have a shock on
routine RM who was unaware of the shock.
Of the patients (n = 13) who were included in the Sprint
Fidelis lead (Medtronic Inc., Minneapolis, MN) recall [2],
9 had RM capability. Two patients were found to have lead
failure on RM before an inappropriate shock was delivered.
One patient had a remote transmission sent *3 months
previously, whereas the other patient had a clinic
appointment *2 months before lead failure both of these
showed normal functioning leads. One patient received an
inappropriate shock related to lead failure and did not had
RM capability. No patients received an inappropriate shock
related to lead failure that had RM capability.
The median interval between last follow-up and occur-
rence of events detected by RM was 46 days (range
1–467), representing a temporal gain of 134 days for
patients followed-up at 6-month intervals and 44 days for
patients followed-up at 3-month intervals. One patient
complained of palpitations, later found to be atrial flutter,
and the device did not detect an arrhythmia because of far-
field oversensing (\0.2 %). One transmission showed an
inappropriate shock when no arrhythmia was present
(\0.2 %). The sensitivity of detecting arrhythmias or
device problems was found to be 99 % (101 of 102),
whereas the specificity was found to be 72 % (369 of 513).
The positive predictive value of RM was found to be 41 %
(101 of 245), whereas the negative predictive value was
99 % (369 of 370). There were 144 false-positive remote
tracings identified, mostly secondary to sinus tachycardia
being erroneously identified as a tachyarrhythmia. Five
transmissions showed that the device was not successful at
Table 1 Clinically actionable events
Disease/rhythm-
related
Detected atrial tachycardia/fibrillation in patients requiring pace termination, shock, cardioversion, or medication
adjustment
Detected sustained ventricular tachycardia C5 beats requiring pace termination, shock, cardioversion, or medication
adjustment
Asystole [3-s pause
Device function Elective replacement indicator or end of life present
Lead function Significant changes in atrial or ventricular lead impedance defined as impedance \200 or [2000 X, unstable lead
impedance deemed to be clinically actionable, C50 % change in lead impedance since last interrogation
Increase in pacing voltage threshold C1 V compared with the previous interrogation
Fig. 1 Percentage of patients with clinically actionable events
transmitted by RM services according to clinical concerns. AF/
F atrial fibrillation/flutter, SVT supraventricular tachycardia, VT/VF
ventricular tachycardia/ventricular fibrillation, ERI/EOL elective
replacement indicator/end of life, LF lead failure
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terminating the event, and further medical management
was needed (0.8 %). To further distinguish between remote
transmissions for routine follow-up compared with those
for specific indications, the sensitivity of routine RM was
found to be 100 % (60 of 60), whereas the specificity was
found to be 77 % (309 of 401). The sensitivity of RM for a
specific indication was found to be 98 % (42 of 43),
whereas the specificity was found to be 54 % (60 of 111).
The positive predictive value of routine RM was found to
be 39 % (60 of 152), whereas the negative predictive value
was 100 % (309 of 309). The positive predictive value of
RM for specific indications was found to be 45 % (42 of
93), whereas the negative predictive value was 98 % (60 of
61).
Of the 36 patients (18 %) who did not submit remote
transmissions, 16 (44 %) were noncompliant; 5 (14 %) did
not receive insurance reimbursement; 4 (11 %) did not
have access to a land-line telephone; 1 (3 %) died; and 10
(28 %) for because of unknown causes. Of the patients who
did not submit because of unknown causes, 5 (50 %) had a
loop-recorder device.
In 2007, there were 4 transmissions; in 2008 there were
25 transmissions; in 2009 there were 161 transmissions; in
2010 there were 200 transmissions; and in 2011 there were
225 transmissions (Fig. 3). In 2011, there was a mean of
0.6 remote transmissions/day, equating to *4 transmis-
sions/week. Time spent by the pacemaker nurse practi-
tioner with analyzing and documenting transmissions
averages 30 min for a noncomplicated pacemaker, ICD,
and loop-recorder interrogation. For more complicated
interrogations, the time spent varies and can take B1 h.
Discussion
RM is designed for early identification of arrhythmias and
device malfunctions, which can ultimately prompt earlier
corrective measures and improve care and safety in pedi-
atric patients. Our study shows that both goals are achieved
in the pediatric population. Of 615 total transmissions,
16 % had true adverse events, 11 % of which prompted
clinical intervention. Of those events requiring clinical
response, 39 % of patients did not have clinical symptoms.
The median interval between last follow-up and occurrence
of events detected by RM was 46 days, representing a gain
of 134 days for patients followed-up at 6-month intervals
and 44 days for patients followed-up at 3-month intervals.
Two patients were found to have lead failure on RM before
an inappropriate shock was delivered. No patients received
an inappropriate shock related to lead failure that had RM
capability.
RM allows for storage of large amounts of data
regarding device function, diagnostics, delivered therapy,
and intracardiac hemodynamics [3]. Obtaining and evalu-
ating these data in a timely manner requires the coopera-
tion of both the provider and the patient. Patient
compliance with sending remote transmissions compared
with standard guidelines was evaluated. Our data show that
the median time between transmissions for all CIEDs was
approximately 3 months. The standard guidelines pub-
lished by the HRS/EHRA consensus paper recommend that
a minimum interval of CIED RM should be 3–12 months
for pacemakers and CRT-P, 3–6 months for ICD/CRT-D,
and 1–6 months for implantable loop recorders [9]. Our
A BFig. 2 a Percentage of patients
with symptoms versus no
symptoms associated with a
clinically actionable remote
transmission. b Percentage of
patients with symptoms grouped
by concerns related to disease/
rhythm, device function, and
lead function
Fig. 3 Number of remote transmissions from 2006 to 2011
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study shows that pediatric patients with CIEDs appropri-
ately adhere to RM procedures. We found that only 18 %
of patients never submitted a remote transmission.
Although most of this was accounted for by patient non-
compliance, some was due to the refusal of the insurance
company to reimburse for this expense as well as the
unavailability of a land-line telephone. Technological
improvements of RM, especially as use of land-line tele-
phones decreases may improve compliance. Those that do
not comply have a much greater chance of later detection
of arrhythmias and device malfunctions that may lead to
increased morbidity and mortality.
We found that using RM affords a temporal gain of
134 days from last follow-up to occurrence of an event for
patients followed-up at 6-month intervals. These data are
similar to the AWARE data, which found a decrease of
154 days, and the COMPAS data, which found a decrease
of 144 days compared with conventional 6-month follow-
up in the adult population [4, 5]. More importantly, earlier
detection of device and/or lead malfunction may improve
patient safety because these were found to be associated
with patient symptoms only 5 % of the time and none of
the time, respectively. This is especially important in the
pediatric population where children’s ability to describe
symptoms and interpretation of their descriptions may be
challenging. For example, our study found that two patients
had lead failure on RM included in the lead recall before an
inappropriate shock was delivered. In addition, RM
detected a shock delivered for ventricular fibrillation dur-
ing the night in a patient who was not aware of receiving
any therapy. RM was able to prevent an inappropriate
shock and to detect an appropriate shock in an asymp-
tomatic patient, thus improving the care and safety of
pediatric patients.
In addition, our data suggest that RM can serve as a
reliable monitoring tool in providing pediatric patients,
their families, and physicians with a comfort level
regarding evaluation of device or patient issues when
concerns do arise. We found that 99 % of the time, if there
is no alert present on RM, the patient is not having a
concerning problem or device issue. Therefore, with RM in
place, patients and their families can feel confident that if
no alert is present, neither the device nor the patient is
currently experiencing problems. In cases where the alert
indicates a concerning device or patient problem, our data
show that only 41 % of the time this is a true concerning
device or patient problem. Consequently, RM can serve as
a monitoring tool to help rule out concerning events;
however, this must be analyzed closely to rule in con-
cerning events. When comparing routine RM versus RM
for specific indications, no difference was seen in sensi-
tivity, positive or negative predictive value. There was a
decrease in the specificity of RM for a specific indication
probably secondary to an increase in false-positive
transmissions.
RM has the potential to allow for fewer clinic visits of
the rapidly growing and more mobile patient population
[7]. The HRS/EHRA consensus paper on CIEDs suggests
that it is safe to decrease the number of clinic visits for ICD
and CRT-devices to annually provided that a transmission
is submitted every 3–6 months [9]. Decreased number of
clinic visits is certainly desirable for patient and physician
time management and may prove to be cost-effective. Our
study shows that patients are appropriately compliant with
routine transmissions, thus providing physicians with
reassurance that patients will not likely go an entire year
without follow-up. Only 14 % of patients (n = 23) went
[1 year without sending a remote transmission. Our study
also showed that RM is a reliable monitoring tool for
evaluating patient and/or device concerns and also showed
that problems were detected weeks to months before face-
to-face encounters would have detected a problem. This
suggests that it could be safe to decrease the number clinic
visits for a subset of patients with CIEDS from every
6 months to annually provided they are compliant with
RM.
The now ‘‘virtual patient’’ created by RM creates a
paradigm shift. Physician practices have the responsibility
of responding to these new sources of patient data, cre-
ating appropriate documentation for reimbursement and
scheduling future device downloads [6]. With the
increased use of RM, methods are needed to manage the
flow of information. It remains to be well-documented
how much time is needed to deal with these alerts. With
the increase in CIED implantations over the recent years,
our study showed that there has been an exponential
increase in the number of remote transmissions. Since
2009, the number of remote transmissions has increased
by an average of 32 transmissions/year, representing a
14 % increase in 2011. There are currently no practice
guidelines on the role of remote follow-up addressing the
previously mentioned concerns. However, there is a need
for an infrastructure and a protocol to address the issue of
these notifications as the volume of remote data continues
to increase. Manpower, operational and organization flow
is an area that requires further exploration and analysis.
Reimbursement and cost-effectiveness have not been
thoroughly evaluated, and this is beyond the scope of this
article. Future studies are certainly needed to address
these important issues.
Some study limitations that should be noted. This study
addressed only those patients with CIEDs who sent a
remote transmission. Documentation of why patients did
not send remote transmissions could not always be
obtained. Patient compliance with RM may limit the
number of transmissions and accuracy of the data. Patient
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recall and reporting of symptoms may not be accurate and
lead to recall bias.
Conclusion
RM allows for early identification of arrhythmias and
device malfunctions, thus prompting earlier corrective
measures in pediatric patients. Families are compliant with
the use of the technology. RM can improve the care and
safety of pediatric patients.
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